Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinC57BL/6JMalen = Echocardiography in six mice per group; n = 10 per group fo…Tail vein injection for AAV9 delivery; intramyocardial injection into the left ventricle for the adenoviral Nrf2 shRNAPre-treatment: AAV9-miR-200a given 4 weeks before doxorubicin challenge
Model: Doxorubicin-induced cardiotoxicity; acute model using a single intraperitoneal injection of DOX-HCl at 15 mg/kg and chronic model using intraperitoneal DOX at 5 mg/kg weekly for four injections (cumulative dose 20 mg/kg)
miR-200a was decreased in doxorubicin-treated hearts. AAV9-mediated miR-200a overexpression restored cardiac miR-200a, blunted body weight loss, prevented the rise in cTnI and NT-proBNP, and preserved +dP/dt, ejection fraction and cardiac output after acute doxorubicin. It preserved the GSH/GSSG ra…
Extraction: extract · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.